Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.62 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866483 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2LPAR3LPAR1CNR1 | |
| SCHEMBL12148896 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2LPAR3LPAR1CNR1 | |
| SCHEMBL1866485 | 1.00 | SLC6A5 (0.64) | SLC6A5EPHX2LPAR3LPAR1CNR1 | |
| SCHEMBL16552975 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL12667224 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL16553079 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL12667229 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL16553206 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL13561439 | 0.96 | CNR1 (0.60) | SLC6A5EPHX2CNR1 | |
| SCHEMBL24073302 | 0.92 | LPAR3 (0.64) | EPHX2LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3434259-A1 | AMINO ACID LIPIDS AND USES THEREOF | Marina Biotech, Inc. (US) | 2019-01-30 | — | — | EP | disclosed |
| US-9731016-B2 | Tyrosine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9731016-B2 | Tyrosine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | MARINA BIOTECH INC (US) | 2016-07-21 | — | — | US | disclosed |
| US-9339461-B2 | Arginine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9339461-B2 | Arginine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2902013-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | Marina Biotech, Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MARINA BIOTECH INC (US) | 2015-07-30 | — | — | US | disclosed |
| US-20110177160-A1 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7939505-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939505-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| WO-2010059829-A2 | COMPOSITIONS AND METHODS FOR TRIGGERED RELEASE RNA THERAPEUTICS | MDRNA, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010045512-A2 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | MDRNA , INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008137758-A2 | AMINO ACID LIPIDS AND USES THEREOF | MDRNA, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206739-A1 | TYROSINE-BASED LIPIDS FOR DELIVERY OF THERAPEUTICS | ABL1, LCK, ERBB2 | SLC6A5 1755/4885EPHX2 2326/4885LPAR3 143/4885 |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | AADAT, AARS1, ABAT | SLC6A5 946/4885EPHX2 3278/4885LPAR3 260/4885 |
| US-20150209283-A1 | PROCESSES AND COMPOSITIONS FOR LIPOSOMAL AND EFFICIENT DELIVERY OF GENE SILENCING THERAPEUTICS | SLC27A2, LYPLA2, SLC27A1 | SLC6A5 602/4885EPHX2 3723/4885LPAR3 588/4885 |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | SLC27A2, LYPLA2, SLC47A2 | SLC6A5 890/4885EPHX2 3928/4885LPAR3 581/4885 |
| US-20110177160-A1 | Amino acid lipids and uses thereof | AADAT, AARS1, ABAT | SLC6A5 946/4885EPHX2 3278/4885LPAR3 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.